文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

成人镰状细胞病单倍体造血干细胞移植后脑血流动力学变化

Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入11例成人镰状细胞病(SCD)患者,比较单倍体骨髓移植(haplo-BMT)前约1个月与移植后12至24个月的脑血流(CBF)、氧摄取分数(OEF)和脑氧代谢率(CMRO2),并与28名年龄、种族、性别匹配的健康成人对比。移植前CBF升高(69.11 ± 24.7 mL/100 g/min,P = .004),移植后CBF显著下降至48.2 ± 13.9 mL/100 g/min(P = .003),与对照组无显著差异(P = .78);OEF和CMRO2移植前后无显著变化。主要并发症包括1例感染相关死亡和1例严重慢性移植物抗宿主病。

要点

  • 成人SCD患者单倍体骨髓移植前CBF升高,移植后CBF显著下降至健康对照水平。
  • 移植后OEF和CMRO2与移植前无显著差异,且与健康对照无显著差异。
  • 单倍体骨髓移植主要并发症包括1例感染相关死亡和1例严重慢性GVHD。

核心结论

  • 成人SCD患者接受单倍体骨髓移植后CBF降至健康对照水平,OEF和CMRO2平均维持在健康成人对照水平。

研究设计与样本

  • 研究纳入11例成人SCD患者(年龄33.3 ± 8.9岁),移植后389 ± 150天进行MRI测量,并与28名年龄、种族、性别匹配的健康成人(年龄30.2 ± 5.6岁)对比。
  • 所有患者接受来自一级亲属(父母、兄弟姐妹或子女)的单倍体骨髓移植,采用减低强度预处理,并维持植入。
  • 移植前7例患者有神经系统移植指征(如显性卒中),4例因非神经系统原因接受单倍体骨髓移植。

主要发现

  • 移植前CBF为69.11 ± 24.7 mL/100 g/min,高于对照(P = .004);移植后CBF为48.2 ± 13.9 mL/100 g/min,较移植前显著下降(P = .003)。
  • 移植后CBF为48.2 ± 13.4 mL/100 g/min,与对照无显著差异(P = .78)。
  • OEF移植前为43.1 ± 6.7%,移植后为39.6 ± 7.0%,变化无显著差异(P = .34);移植后与对照无显著差异(P > .99)。
  • CMRO2移植前为3.18 ± 0.87 mL O2/100 g/min,移植后为2.95 ± 0.83 mL O2/100 g/min,变化无显著差异(P = .56)。
  • 主要并发症包括1例感染相关死亡和1例严重慢性移植物抗宿主病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preliminary evidence from a series of 4 adults with sickle cell disease (SCD) suggests that hematopoietic stem cell transplant (HSCT) improves cerebral hemodynamics. HSCT largely normalizes cerebral hemodynamics in children with SCD. We tested the hypothesis in adults with SCD that cerebral blood flow (CBF), oxygen extraction fraction (OEF), and cerebral metabolic rate of oxygen (CMRO2) measured using magnetic resonance imaging, normalized to healthy values, comparing measurements from ∼1 month before to 12 to 24 months after HSCT (n = 11; age, 33.3 ± 8.9 years; 389 ± 150 days after HSCT) with age-, race- and sex-matched values from healthy adults without sickle trait (n = 28; age, 30.2 ± 5.6 years). Before transplant, 7 patients had neurological indications for transplant (eg, overt stroke) and 4 had nonneurological reasons for haploidentical bone marrow transplant (haplo-BMT). All received haplo-BMT from first-degree relatives (parent, sibling, or child donor) with reduced-intensity preparation and maintained engraftment. Before transplant, CBF was elevated (CBF, 69.11 ± 24.7 mL/100 g/min) compared with that of controls (P = .004). Mean CBF declined significantly after haplo-BMT (posttransplant CBF, 48.2 ± 13.9 mL/100 g/min; P = .003). OEF was not different from that of controls at baseline and did not change significantly after haplo-BMT (pretransplant, 43.1 ± 6.7%; posttransplant, 39.6 ± 7.0%; P = .34). After transplant, CBF and OEF were not significantly different from controls (CBF, 48.2 ± 13.4 mL/100 g/min; P = .78; and OEF, 39.6 ± 7.0%; P > .99). CMRO2 did not change significantly after haplo-BMT (pretransplant, 3.18 ± 0.87 mL O2/100 g/min; posttransplant, 2.95 ± 0.83; P = .56). Major complications of haplo-BMT included 1 infection-related death and 1 severe chronic graft-versus-host disease. Haplo-BMT in adults with SCD reduces CBF to that of control values and maintains OEF and CMRO2 on average at levels observed in healthy adult controls. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aumann MA, Richerson W, Song AK, et al. Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease. Blood Adv. 2024. PMID: 37883803. doi:10.1182/bloodadvances.2023010717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。